As of close of business last night, Regenxbio Inc’s stock clocked out at $21.53, up 2.18% from its previous closing price of $21.07. In other words, the price has increased by $+0.46 from its previous closing price. On the day, 536337 shares were traded. RGNX stock price reached its highest trading level at $21.57 during the session, while it also had its lowest trading level at $20.65.
Ratios:
To gain a deeper understanding of RGNX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.57 and its Current Ratio is at 2.57. In the meantime, Its Debt-to-Equity ratio is 0.29 whereas as Long-Term Debt/Eq ratio is at 0.26.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on March 11, 2024, initiated with a Buy rating and assigned the stock a target price of $36.
On March 08, 2024, RBC Capital Mkts Upgraded its rating to Outperform which previously was Sector Perform and also upped its target price recommendation from $20 to $35.
Leerink Partners Upgraded its Market Perform to Outperform on March 06, 2024, while the target price for the stock was maintained at $37.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 14 ’24 when Mills Kenneth T. sold 15,000 shares for $21.86 per share. The transaction valued at 327,942 led to the insider holds 408,035 shares of the business.
PAKOLA STEVE sold 12,878 shares of RGNX for $365,220 on Mar 05 ’24. The Chief Medical Officer now owns 107,192 shares after completing the transaction at $28.36 per share. On Feb 14 ’24, another insider, Mills Kenneth T., who serves as the President and CEO of the company, sold 15,000 shares for $16.76 each. As a result, the insider received 251,349 and left with 408,035 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RGNX now has a Market Capitalization of 1.05B and an Enterprise Value of 868.85M. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.69 while its Price-to-Book (P/B) ratio in mrq is 3.04. Its current Enterprise Value per Revenue stands at 9.63 whereas that against EBITDA is -3.63.
Stock Price History:
The Beta on a monthly basis for RGNX is 1.29, which has changed by 10.20% over the last 52 weeks, in comparison to a change of 28.14% over the same period for the S&P500. Over the past 52 weeks, RGNX has reached a high of $28.80, while it has fallen to a 52-week low of $11.83. The 50-Day Moving Average of the stock is 18.26, while the 200-Day Moving Average is calculated to be 17.96.
Shares Statistics:
It appears that RGNX traded 796.16K shares on average per day over the past three months and 597.44k shares per day over the past ten days. A total of 44.05M shares are outstanding, with a floating share count of 43.91M. Insiders hold about 10.38% of the company’s shares, while institutions hold 79.22% stake in the company. Shares short for RGNX as of Mar 15, 2024 were 4.15M with a Short Ratio of 5.21, compared to 4.17M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 8.47% and a Short% of Float of 10.64%.
Earnings Estimates
As of right now, 10 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$1.26 for the current quarter, with a high estimate of -$1.11 and a low estimate of -$1.5, while EPS last year was -$1.53. The consensus estimate for the next quarter is -$1.22, with high estimates of -$1.06 and low estimates of -$1.4.
Analysts are recommending an EPS of between -$1.41 and -$5.66 for the fiscal current year, implying an average EPS of -$4.53. EPS for the following year is -$2.19, with 11 analysts recommending between $1.45 and -$5.15.
Revenue Estimates
In the current quarter, 8 analysts expect revenue to total $23.52M. It ranges from a high estimate of $34.7M to a low estimate of $16.69M. As of the current estimate, Regenxbio Inc’s year-ago sales were $19.14M, an estimated increase of 22.90% from the year-ago figure.
A total of 12 analysts have provided revenue estimates for RGNX’s current fiscal year. The highest revenue estimate was $284.76M, while the lowest revenue estimate was $80M, resulting in an average revenue estimate of $133.61M. In the same quarter a year ago, actual revenue was $90.24M, up 48.10% from the average estimate. Based on 12 analysts’ estimates, the company’s revenue will be $234.7M in the next fiscal year. The high estimate is $414M and the low estimate is $80M. The average revenue growth estimate for next year is up 75.70% from the average revenue estimate for this year.
